Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 7;4(3):100972. doi: 10.1016/j.xcrm.2023.100972

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Authors

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

ctDNA dynamics and correlation with treatment response

(A and B) The Kaplan-Meier curves of (A) PFS and (B) OS of patients stratified by change of ctDNA (T1-T2 mVAF decline vs. non-decline).

(C) Treatment response of patients stratified by change of ctDNA (T1-T2 mVAF decline vs. non-decline).

(D and E) The Kaplan-Meier curves of (D) PFS and (E) OS of patients stratified by decline of ctDNA (T1-T2 mVAF > 50% vs. < 50%).

(F) Treatment response of patients stratified by decline of ctDNA (T1-T2 mVAF > 50% vs. < 50%).

(G and H) Clinical outcome (G) and postoperation pathological stage (H) of the patients stratified by decline of ctDNA (T1-T2 mVAF > 50% vs. < 50%).

ctDNA, circulating tumor DNA; T1, baseline; T2, two cycles after therapy; mVAF, maximal somatic variant allelic frequency; PR, partial response; SD, stable disease; MPR, major pathological response.